Table 2.

Effect of l-NMMA, SNP and angiotensin II on blood pressure, heart rate, and vascular tone in SCI and controls

	SCI (n = 7)					Controls (n = 7)
	MAP	HR	LBF	LVR		MAP	HR	LBF	LVR
Drug (Does min−1 dl−1				Infusion	Control				Infusion	Control
l-NMMA
Saline	91 ± 4	57 ± 4	2.8 ± 0.5	37 ± 4	34 ± 5	98 ± 4	57 ± 3	3.3 ± 0.2	31 ± 2	33 ± 2
0.025 mg	91 ± 4	58 ± 5	2.4 ± 0.4	43 ± 5	36 ± 4	100 ± 5	56 ± 3	2.6 ± 0.2	40 ± 3	35 ± 2
0.05 mg	94 ± 4	56 ± 5	2.2 ± 0.4	47 ± 5	33 ± 4	99 ± 4	58 ± 3	2.6 ± 0.1	40 ± 3	35 ± 2
0.1 mg	95 ± 5	55 ± 6	1.9 ± 0.3	56 ± 7	36 ± 5	100 ± 4	57 ± 3	2.3 ± 0.2	47 ± 4	33 ± 3
0.2 mg	96 ± 4	53 ± 4	1.8 ± 0.3	71 ± 16	37 ± 6	102 ± 4	55 ± 3	2.2 ± 0.1	49 ± 3	33 ± 3
0.4 mg	101 ± 4	54 ± 4	1.6 ± 0.2	71 ± 11	39 ± 5	105 ± 4	57 ± 3	2.1 ± 0.1	52 ± 3	30 ± 2
	*	*	*	*	†	*	*	*	*	‡
SNP
Glucose	104 ± 4	53 ± 4	2.0 ± 0.2	54 ± 5	40 ± 7	109 ± 3	55 ± 5	2.9 ± 0.2	39 ± 2	30 ± 3
0.06 μg	105 ± 4	52 ± 5	3.1 ± 0.5	37 ± 4	42 ± 5	106 ± 4	58 ± 4	4.9 ± 0.6	25 ± 4	34 ± 3
0.2 μg	92 ± 4	56 ± 5	4.4 ± 0.8	25 ± 3	35 ± 5	101 ± 5	58 ± 4	5.3 ± 0.6	21 ± 3	39 ± 6
0.6 μg	83 ± 4	64 ± 5	5.5 ± 1.0	18 ± 2	33 ± 7	96 ± 5	67 ± 5	7.7 ± 0.9	15 ± 3	35 ± 6
	*	*	*	*		*	*	*	*
Ang II
Saline	103 ± 4	56 ± 5	2.2 ± 0.4	56 ± 12	43 ± 7	105 ± 4	60 ± 5	3.1 ± 0.4	37 ± 5	34 ± 3
0.25 ng	106 ± 3	56 ± 5	1.7 ± 0.3	80 ± 18	46 ± 9	109 ± 5	61 ± 6	2.4 ± 0.3	51 ± 6	34 ± 3
0.5 ng	106 ± 4	55 ± 5	1.5 ± 0.3	105 ± 32	55 ± 20	109 ± 5	63 ± 6	2.3 ± 0.2	53 ± 6	33 ± 3
2.0 ng	112 ± 5	57 ± 6	1.4 ± 0.3	124 ± 36	55 ± 17	112 ± 5	62 ± 5	1.8 ± 0.2	73 ± 12	32 ± 4
	*		*	*		*		*	*

MAP, mean arterial pressure (mmHg); HR, heart rate (beats min⁻¹); LBF, leg blood flow (ml min⁻¹ dl⁻¹); LVR, leg vascular resistance (AU); Infusion, the infused leg; Control, the non-infused leg. Ang II, angiotensin II.

^*Significant dose effect for both groups(P < 0.05, two-way-ANOVA).

^†Trend to significant interaction for dose × group (P = 0.069).

^‡Significant dose effect(P<0.05, one-way ANOVA).